| 2026-06-18 | Press release | GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis |
| 2026-05-14 | Press release | GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopat |
| 2026-04-08 | Press release | GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the |
| 2026-02-05 | Press release | GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial |
| 2026-02-04 | Press release | GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights |
| 2026-01-28 | Press release | GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and |
| 2026-01-26 | Press release | GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures |
| 2026-01-21 | Press release | GRI Bio Announces Reverse Stock Split |
| 2026-01-08 | Press release | GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical |
| 2025-12-12 | Press release | GRI Bio Announces Closing of $8.0 Million Public Offering |
| 2025-12-11 | Press release | GRI Bio Announces Pricing of $8,000,000 Public Offering |
| 2025-12-10 | Press release | GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) |
| 2025-09-11 | Press release | GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF |
| 2025-09-03 | Press release | GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference |
| 2025-08-14 | Press release | GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech |
| 2025-07-31 | Press release | GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPFR |
| 2025-07-31 | Press release | GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment |
| 2025-07-22 | Press release | GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference |
| 2025-07-01 | Press release | GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IP |
| 2025-06-26 | Press release | GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study |
| 2025-05-22 | Press release | GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induc |
| 2025-05-21 | Press release | GRI Bio to Participate in the Virtual Investor Closing Bell Series |
| 2025-05-16 | Press release | GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase |
| 2025-05-15 | Press release | GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interi |
| 2025-05-08 | Press release | GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Pat |
| 2025-05-07 | Press release | GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF |
| 2025-05-07 | Press release | GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF |
| 2025-04-16 | Press release | GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) Internatio |
| 2025-04-02 | Press release | GRI Bio Announces Closing of $5.0 Million Public Offering |
| 2025-04-01 | Press release | GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonar |
| 2025-04-01 | Press release | GRI Bio Announces Pricing of $5.0 Million Public Offering |
| 2025-03-31 | Press release | GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan |
| 2025-03-18 | Press release | GRI Bio Participates in a Virtual Investor CEO Connect Segment |
| 2025-03-17 | Press release | GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phas |
| 2025-03-11 | Press release | GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule |
| 2025-02-19 | Press release | GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for '25” On-Demand Conference |
| 2025-02-19 | Press release | GRI Bio Announces Reverse Stock Split |
| 2024-12-23 | Press release | GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library |
| 2024-12-06 | Press release | GRI Bio to Participate in the Virtual Investor Closing Bell Series |
| 2024-11-21 | Press release | GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathi |